Zhang Li, Wan Zhen-Xia, Zhu Jin-Yi, Liu Hui-Juan, Sun Jin, Zou Xiao-Hui, Zhang Ting, Li Yan
Research Center for Child Health, Department of Child Health Care, Key Laboratory of Birth Regulation and Control Technology of National Health Commission of China, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.
Neonatal Intensive Care Unit, Key Laboratory of Birth Regulation and Control Technology of National Health Commission of China, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.
Case Rep Pediatr. 2024 Feb 16;2024:5539799. doi: 10.1155/2024/5539799. eCollection 2024.
Benign familial infantile seizure (BFIS) is an autosomal dominant infantile-onset epilepsy syndrome with a typically benign prognosis. It is commonly associated with heterozygous mutations of the gene located on chromosome 16p11.2. The frameshift heterozygous mutation (c.649dupC, p.Arg217Profs8) in is responsible for the majority of BFIS cases. In this report, we present a rare case of a girl with a confirmed clinical and genetic diagnosis of BFIS due to a frameshift heterozygous mutation in (c.649dupC). She exhibited typical neurodevelopment until 15 months of age, followed by an unexpected severe autistic regression. In addition to BFIS, mutations are also associated with paroxysmal kinesigenic dyskinesia (PKD) and infantile convulsions and paroxysmal choreoathetosis (ICCA), indicating a complex genotype-phenotype heterogeneity in mutations. This clinical observation highlights the possibility that BFIS patients with mutations may not always have a benign neurodevelopmental prognosis, emphasizing the need for long-term clinical follow-up.
良性家族性婴儿惊厥(BFIS)是一种常染色体显性遗传的婴儿期起病的癫痫综合征,预后通常良好。它通常与位于16号染色体p11.2上的基因杂合突变有关。该基因的移码杂合突变(c.649dupC,p.Arg217Profs8)是大多数BFIS病例的病因。在本报告中,我们介绍了一例罕见病例,一名女孩因该基因(c.649dupC)的移码杂合突变而被确诊为临床和基因诊断的BFIS。她在15个月大之前表现出典型的神经发育,随后出现了意外的严重自闭症倒退。除了BFIS,该基因突变还与发作性运动诱发性运动障碍(PKD)以及婴儿惊厥和阵发性舞蹈手足徐动症(ICCA)有关,这表明该基因突变存在复杂的基因型-表型异质性。这一临床观察结果凸显了携带该基因突变的BFIS患者可能并非总是具有良好神经发育预后的可能性,强调了长期临床随访的必要性。